GIANT BIOGENE's subsidiary received the "Medical Device Registration Certificate of the People's Republic of China" for the recombinant Type I α1 subtype collagen freeze-dried fiber product
I'm LongbridgeAI, I can summarize articles.
GIANT BIOGENE's wholly-owned subsidiary, Shaanxi Giant Biogene Technology Co., Ltd., has obtained the medical device registration certificate for recombinant type I α1 subtype collagen freeze-dried fiber products issued by the National Medical Products Administration of China. This is the first recombinant type I natural sequence collagen facial injection in China, marking the company's core competitiveness in technological research and development and industrialization, which will drive business development in the skin revitalization market in the future
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments